
Moderna, Inc. (NASDAQ:MRNA) rose to prominence with its messenger RNA-based COVID-19 vaccine. The stock capitalized on the catalyst and ran up from obscurity to respectable levels.
The stock rally has cooled amid fears regarding the sustainability of the strength induced by the COVID-19 vaccine.